Introduction
The phenomenon of tolerance has evolved to allow the immune system to distinguish between self from nonself, largely to prevent pathologic reactivity against self antigens (Pardoll, 2003) . However, tumors cells can activate tolerance signaling pathways that are critical for normal homeostasis of the immune system, resulting in immune tolerance to cancer cells. Dynamic interactions between cancer cells and tumor-associated immune cells initiate and maintain tumor immune tolerance, which eventually predominates and mitigates effective host immune response (Elgert et al., 1998; Pardoll, 2003) . Among immune cells, macrophages constitute one of the major components of immune cell infiltrate observed in the tumor microenvironment (TME) of many types of malignancies, including lung cancer (Bingle et al., 2002) . Although macrophages can mediate tumor cytotoxicity and present tumor-associated antigens to stimulate anti-tumor lymphocyte responses, cancer cells routinely circumvent these macrophagemediated immune responses. Tumor-associated macrophages (TAMs) are a distinct macrophage phenotype mimicking the phenotype of alternatively activated or M2 macrophages (Mantovani et al., 2002) . These M2 cells have poor antigen presenting capability, produce factors that suppress T-cell proliferation and activity, and are generally better adapted to scavenging debris, promoting angiogenesis and remodeling wounded tissues.
Accumulating evidence demonstrates that cancer cells not only overcome anti-tumor activities of macrophages, but also actively redirect TAM activities toward promoting tumor progression and metastasis by altering the function and phenotype of TAMs (Bingle et al., 2002) . These cells are implicated in several key aspects of tumor progression, including tumor cell proliferation, survival, angiogenesis and metastasis (Lewis and Pollard, 2006; Yamaguchi et al., 2006) . Many tumorderived molecules, including tumor growth factor-b (TGF-b) deactivate or suppress the cytotoxic activity of TAMs (Elgert et al., 1998) . This notion that TAMs promote tumor progression is supported by the observation that a high density of TAMs correlates with a poor prognosis in patients with cancer (Bingle et al., 2002; Pollard, 2004; Balkwill et al., 2005) . In addition, studies involving macrophage-depleted mice have causally linked the presence of TAMs with poor prognosis (Johnson et al., 2000) .
Toll-like receptors (TLRs) are critical components of innate immune responses in macrophages Schnare et al., 2001; Akira and Takeda, 2004) . Activation of TLR-family members triggers the induction of several cytokines involved in anti-tumor responses, including TNF-a, IL-12 and interferon-g (IFN-g; Seya et al., 2003) . In the TME, the exact trigger(s) of TLR signaling in macrophages is not known. However, the TME is rich in molecules that can potentially activate macrophage TLR signaling to trigger anti-tumor responses; including heat shock proteins, high mobility group proteins, double-stranded DNA from necrotic tumor cells and hyaluronic acid (Elgert et al., 1998; Ben-Baruch, 2006) . Following recognition of pathogen-associated molecular patterns, the TLR receptors bind intracellular adapter proteins, including MyD88 and TIR domain-containing adapter protein/Mal, which in turn recruit other serine/ threonine kinases implicated in inflammation signaling (for example, interleukin receptor-associated kinase (IRAK)-1, IRAK-4 and TRAF6). In contrast, IRAK-M is an inactive kinase that antagonizes TLR signaling through protein-protein interactions preventing downstream activation of IRAK-1 (Kobayashi et al., 2002) . IRAK-M is regarded as a key negative regulator of TLR signaling in macrophages (Kobayashi et al., 2002) . However, studies implicating a role for IRAK-M in other cell types are also emerging (Wesche et al., 1999; Rosati and Martin, 2002) . The presence of IRAK-M is critical for inactivating innate immune signals and prevents excessive inflammatory responses (Kobayashi et al., 2002) . Unfortunately, in pathologies, such as sepsis and cancer, immune suppressive function of IRAK-M is exploited to evade host immune surveillance (del Fresno et al., 2005; Deng et al., 2006) . TGF-b is a multifunctional cytokine with dual and paradoxical roles in cancer biology. In early stages of carcinogenesis, this cytokine functions as a tumor suppressor, whereas in late stages TGF-b functions as a tumor promoter (Elliott and Blobe, 2005) . Consistent with the tumor promoting function, TGF-b expression is frequently upregulated in non-small cell lung cancer (Kim et al., 1999) and elevated plasma levels of TGF-b confer a poor prognosis in patients with lung cancer (Kong et al., 1999) . As part of its tumor promoting effects, TGF-b has a broad influence on the immune system partly through cross-talk between TGF-b signaling intermediates and the components of both cytokine and antigen receptors, including TLRs (Li et al., 2006) . In this study, we show that TGF-bmediated induction of IRAK-M in TAMs, serve as a key mechanism by which lung tumors, may circumvent anti-tumor responses of macrophages promoting tumor immune tolerance.
Results
TAMs express significantly higher IRAK-M and produce low levels of IL-12, IFN-g and TNF-a as compared with peritoneal macrophages (PEMs) It is well recognized that TAMs are defective in the production of proinflammatory and immunoregulatory cytokines such as IL-12, IFN-g and TNF-a. As IRAK-M is a negative regulator of pro-inflammatory TLR signaling, we assessed whether IRAK-M expression correlates with defective cytokine production by TAMs. For this analysis, TAMs were isolated from Lewis lung carcinoma (LLC) tumor tissue harvested from the WT C57/B6 mice, whereas thioglycolate-elicited PEMs were obtained by peritoneal lavage from the same mice. As expected, we observed very low levels of IL-12, IFN-g and TNF-a production in TAMs, compared with PEMs ( Figure 1a) , as assessed by real-time PCR. Interestingly, several fold greater IRAK-M expression, both at RNA and protein levels, was observed in TAMs compared with PEMs (Figures 1b and c) . This observation suggests that IRAK-M may mediate the immunosuppressive TAM phenotype observed in tumors.
Inhibition of LLC tumor growth in IRAK-M
À/À mice To determine whether IRAK-M has a role in immune surveillance against tumors, we subcutaneously implanted LLC cells into IRAK-M þ / þ and IRAK-M À/À mice (six each) on both sides of the dorsal flank. Tumor growth was monitored by bi-weekly measurements for 3 weeks total. Average tumor volume for each group is plotted ( Figure 2a mice. However, IL-12 levels in the tumors from IRAK-M À/À mice were several fold higher than that measured in tumors from IRAK-M þ / þ mice. This suggests that IRAK-M is a potential regulator of type 1 cytokine production (for example, IL-12), but does not modulate the levels of immunosuppressive cytokine TGF-b.
Enhanced expression of IL-12 and IFN-g in TAMs isolated from IRAK-M À/À compared with WT TAMs As IRAK-M is predominantly expressed in monocytes/ macrophages (Wesche et al., 1999; Kobayashi et al., 2002) , the difference in cytokine production and tumor growth in IRAK-M (Figure 4a ). In contrast, no difference in TNF-a production was observed.
IRAK-M-deficient TAMs express a classically activated rather than alternatively activated phenotype as compared with TAMs from IRAK-M þ / þ mice It is known that TAMs exhibit an alternatively activated or M2 polarized macrophage phenotype, a response that is required to adequately regulate inflammation, tissue remodeling, and repair (Gordon, 2003) . In tumors, the M2 phenotype of TAMs allows subversion of antitumor immunity and facilitates other tumor promoting roles of TAMs (Mantovani et al., 2002) . (Figure 7c ). These results demonstrate that tumor-derived TGF-b is present in the lung TME and may promote evasion of macro- Gene expression of IRAK-M in human lung cancer correlates with poor survival Given the observed tumor promoting activity of IRAK-M, we tested for an association between IRAK-M mRNA levels and survival in a previously described cohort of 439 patients with lung adenocarcinoma using Affymetrix (Santa Clara, Ca, USA) GeneChip array analysis (Shedden et al., 2008) . We fit Cox proportional hazards regression models that included age, gender and stage (I, II or III), which were reported to be significant clinical variables in the original publication (Shedden et al., 2008) . All co-variables were found to be independently correlated with survival (Table 1) . IRAK-M minimum and maximum values differed by 11-fold, and base-2 logarithms had standard deviation of 0.54. Importantly, the magnitude of IRAK-M expression was associated with a relative risk of 1.33 for each doubling of the expression values (P ¼ 0.021) ( Table 1 ). The mean expression of IRAK-M for stages I, II and III were À0.006, 0.018 and 0.024. Even though these means were not significantly different (P ¼ 0.68 comparing stage I versus III by one-way analysis of variance model), their magnitude increased with the stage of the tumor. The similar increased relative risk was observed for male sex and for every additional 10 years of age at time of diagnosis increased risk by a similar amount, as did being male. Stage of disease was the most significant risk factor, with a 2.4-fold increased relative risk for stage II and a nearly 5-fold increased risk for stage III disease. Collectively, this data demonstrates that in addition to age, gender and stage, the magnitude of IRAK-M expression in tumors is an independent predictor of mortality in patients with adenocarcinoma of the lung, even when corrected for other co-variables.
Discussion
Lung cancer is the single most deadly cancer in the world, with 150 000 new cases diagnosed every year in United States alone (Jemal et al., 2005) . General cytotoxic therapies, such as chemotherapy and radiation, are standard of care for both resectable and nonresectable non-small cell lung cancers (Souquet and Geriniere, 2001; Scagliotti and Novello, 2003) , although the 5-year survival rate for lung cancer patients remains o15% (Edwards et al., 2005) . This highlights the urgent need for novel strategies to improve treatment outcomes. Despite the well-recognized role of dynamic interactions between various cell types present within the TME in fostering tumor progression, investigations to define these interactions or to elucidate underlying molecular mechanisms in lung cancer are limited. In this study, we define one such interaction between lung cancer cells and TAMs, including mechanisms involved and clinical relevance to human lung cancer. Macrophages present in healthy tissues can exhibit cytolytic activity against tumor cells, present tumorassociated antigens, and stimulate anti-tumor functions of T-cells (Letterio and Roberts, 1998; Li et al., 2006) . However, TAMs present in the TME often display reduced effector functions, rendering the host incapable of mounting an effective immune response. Instead, cells/factors present within the TME skews TAMs toward a distinct tumor permissive phenotype (Mantovani et al., 1992; Lewis and Pollard, 2006) . The molecular basis for such a distinct tumor promoting phenotype of TAMs and their role in lung cancer progression is yet undefined. It is worth noting that TAMs have distinct roles in different TMEs (Lewis and Pollard, 2006) . For that reason, it is essential to investigate TAM functions in lung tumor models to derive inferences regarding lung cancer-specific roles of TAMs. A blunted inflammatory cytokine response was observed, as manifested by reduced production of IL-12 and IFN-g by TAMs isolated from LLC tumors, similar to the phenotype displayed by TAMs in other malignancies (Mytar et al., 2003) . Conversely, TAMs expressed higher levels of Fizz1 (RELM) and reduced levels of iNOS, reflecting the M2-phenotype of TAMs. Previously it has been shown that lipopolysaccharide tolerance in human endotoxemia models is associated with the upregulation of IRAK-M (van 't Veer et al., 2007; de Vos et al., 2009 ). Analogous to endotoxin tolerance, similar increase in IRAK-M expression was reported in alveolar macrophages during sepsis-induced immune suppression (Deng et al., 2006) and in peripheral blood mononuclear cells (PBMCs) isolated from patients with chronic myeloid leukemia (del Fresno et al., 2005) . Correlating with blunted cytokine responses, we observed significantly elevated levels of IRAK-M in TAMs relative to other macrophage populations (PEMs). This is the first report demonstrating increased IRAK-M expression in macrophages isolated from solid tumors.
It has been shown that IRAK-M is a negative regulator of TLR signaling, as mice deficient in IRAK-M demonstrate enhanced macrophage-mediated innate immunity (Kobayashi et al., 2002) . In addition, IRAK-M À/À mice exhibit striking resistance to the development of immune tolerance. In this study, mice lacking IRAK-M demonstrated greater suppression of syngeneic lung cancer tumor growth as compared with WT mice. Analysis of TAMs isolated from tumors in IRAK-M À/À mice showed a dramatic increase in the production of type 1 cytokines, indicating resistance to the tolerance phenotype of TAMs. However, lack of IRAK-M did not rescue TNF-a production in TAMs, suggesting a potential IRAK-M-independent mechanism. Interestingly, we also noted inhibition of the M2-like phenotype in TAMs isolated from IRAK-M À/À mice, as indicated by reduced Fizz1 and increased iNOS expression. This suggests that IRAK-M, at least in part, is responsible for promoting alternative activation in TAMs. The observed resistance to tumor growth in IRAK-M À/À mice is consistent with an earlier study Regulation of lung tumor progression by IRAK-M TJ Standiford et al using a melanoma tumor model, which attributed increased resistance to elevated populations of CD4 þ and CD8 þ T-cells and a decrease in Foxp3 þ regulatory T-cells in IRAK-M À/À splenocytes (Xie et al., 2007) . The aforementioned study did not assess the phenotype of TAMs, and it is quite plausible that the changes in T-cell populations are reflective of altered TAM phenotype in IRAK-M À/À mice. Tumors are known to evade host immune surveillance by multiple mechanisms, one of which being the production of TGF-b. For that reason, we explored potential regulation of IRAK-M in TAMs by TGF-b. Analysis of tumor lysates showed a dramatic increase in the levels of IL-12 protein in IRAK-M À/À tumors compared with tumors from WT mice. However, there was no difference in the levels of TGF-b protein between the tumors of WT and IRAK-M À/À mice, demonstrating that IRAK-M had no effect on the production of TGF-b in the TME. Interestingly, stimulation of either human PBMCs or murine macrophage cell line RAW 264.7 with TGF-b induced IRAK-M expression in both a dose-and time-dependent manner. Our findings are consistent with a recent study demonstrating a role for TGF-b/Smad4 in lipopolysaccharide-induced IRAK-M expression in THP-1 cells (Pan et al., 2010) . As reported previously for other tumor cell types (del Fresno et al., 2005), we found that human lung cancer cells also induced IRAK-M expression in human PBMCs when co-cultured either in direct contact or separated by a porous membrane, implicating a soluble factor in the induction of IRAK-M. Co-culturing human PBMCs with lung cancer cells in the presence of a pan-TGF-bneutralizing antibody significantly abrogated tumor cell-induced IRAK-M expression in PBMCs, confirming a role for TGF-b in the regulation of IRAK-M expression. Given the pleiotropic biological functions of TGF-b, it is not surprising to observe crossregulation between this cytokine and TLR signaling. For example, investigations in mice lacking a functional TGF-b signaling pathway have revealed aberrantly increased TLR4 expression (McCartney-Francis et al., 2004) . TGF-b has also been shown to inhibit lipopolysaccharide-induced TLR4 signaling by inducing degradation of MyD88, a critical downstream adapter molecule required for the signaling of most TLRs (Naiki et al., 2005) . Consistent with these observations, our findings demonstrate yet another novel mechanism by which TGF-b regulates TAM function in lung tumors.
Analysis of IRAK-M gene expression in human lung adenocarcinoma tumors revealed that high IRAK-M expression in tumors correlated with poor survival in patients with this disease. Given the regulation of IRAK-M by TGF-b, this observation is consistent with earlier reports that TGF-b expression is frequently upregulated in patients with lung cancer (Hasegawa et al., 2001) and elevated plasma levels of TGF-b confer a poor prognosis (Hasegawa et al., 2001; Toonkel et al., 2010) . Together, our data demonstrates that TGF-b-dependent induction of IRAK-M expression is an important and clinically relevant mechanism by which tumors may circumvent anti-tumor responses of macrophages. Thus, we propose that the targeting IRAK-M may represent a viable immunotherapy in the treatment of patients with lung cancer.
Materials and methods

Cell culture
The A549, H460, H522 human non-small cell cancer (NSCLC) cell lines, murine lung cancer cell line, LLC which are syngeneic to C57/BL6 mice and RAW 264.7 murine macrophage cell line were obtained from the American Type Culture Collection. NSCLC, LLC and RAW 264.7 cells were maintained in RPMI-1640 medium with glutamine (Invitrogen, Carlbad, CA, USA), supplemented with 10% fetal bovine serum and antibiotics penicillin and streptomycin.
Isolation of TAMs from tumors
To isolate TAMs, tumor tissue was chopped into small pieces before incubation with an enzyme mixture (400 U/ml collagenase type IV, 0.05 mg/ml collagenase type I, 0.025 mg/ ml hyaluronidase (Sigma-Aldrich, St Louis, MO, USA), 0.01 mg/ml DNAse I, 0.2 U/ml soybean trypsin inhibitor (Boehringer Mannheim, Indianapolis, IN, USA) dissolved in RPMI-1640 for 2 h at 37 1C. Single-cell suspensions were prepared in MACS buffer (degassed phosphate-buffered saline, 0.5% bovine serum albumin, 2 mM EDTA), and incubated (15 min, 8 1C) with anti-CD11b-microbeads (Miltenyi Biotec, Aubum, CA, USA; 5 ml beads/107 cells). CD11b þ cells were purified on LS columns (Miltenyi Biotec), using the MidiMACS system according to the manufacturer's instructions. Cells were plated in Petri dishes, after 1 h of incubation, non-adherent cells were washed off thoroughly and the purity of the preparation was confirmed by morphology and staining with macrophage-specific marker F4/80.
Isolation of human peripheral blood monocytes
Whole blood (anticoagulated with 1000 U of heparin per 60 ml) was obtained by venipuncture from healthy donors, and monocytes were obtained by Ficoll-plaque (Amersham, Uppsala, Sweden) density centrifugation and adherence purification. Cells were cultured in the absence of serum and were stimulated as indicated.
Isolation of PEMs
Cells were obtained by peritoneal lavage from mice injected 4 days previously with 0.5 ml of 3% thioglycolate. Cells were suspended in MACS buffer (degassed phosphate-buffered saline, 0.5% bovine serum albumin, 2 mM EDTA) and incubated (15 min, 8 1C) with anti-CD11b-microbeads (Miltenyi Biotec; 5 ml beads/10 7 cells). CD11b þ cells were purified on LS columns (Miltenyi Biotec) using the MidiMACS system according to the manufacturer's instructions. Cells were plated in Petri dishes, after 1 h of incubation, non-adherent cells were washed off thoroughly and the purity of the preparation was confirmed by morphology and staining with macrophagespecific marker F4/80.
Western blotting
Crude protein extracts were obtained by lysing 5 Â 106 cells in a buffer containing 50 mM Tris-HCl (pH 7.6), 1% Nonidet P-40, 2 mM EDTA, 0.5% sodium deoxycholate, 150 mM NaCl, 1 mM sodium orthovanadate, 2 mM ethylene glycol tetraacetic acid, 4 mM sodium p-nitrophenyl phosphate, 100 mM sodium fluoride and supplemented with protease inhibitors (leupeptin (0.5%), aprotinin (0.5%) and phenylmethylsulfonyl fluoride (0.02%)). Samples containing 20 mg of total protein were electrophoresed on SDS-polyacrylamide gels and transferred on to nitrocellulose membrane by electro blotting. Membranes were probed with antibodies as indicated followed by horseradish peroxidase-conjugated mouse or rabbit secondary antibodies and visualized by West Pico chemiluminescence detection reagents (Pierce, Rockford, IL, USA).
Heterotopic LLC tumor model LLC cells (0.5 Â 10 6 ) suspended in 100 ml of serum-free RPMI-1640 media were implanted subcutaneously on either side of the dorsal flank of C57/BL-6 mice. Tumor growth was monitored by weekly measurements of tumors with calipers. After 21 days, animals were killed and tumors were dissected from the mice, measured for three-dimensional size and photographed. A portion of the tumor was snap-frozen in liquid nitrogen for protein analysis.
Real-time quantitative PCR for IRAK-M Relative expression of IRAK-M was determined by using TaqMan real-time quantitative PCR as described before (Reddy et al., 2004) . Briefly, gene-specific primers and probes were designed using Primer Express software (Perkin-Elmer/PE Applied Biosystems, Foster City, CA, USA). Oligonucleotide primers and TaqMan probe for b-actin internal control was purchased from Perkin-Elmer/PE Applied Biosystems. The realtime quantitative reverse transcriptase-PCR was performed following the manufacturer's protocol. Briefly, the reaction mixture contained 5.5 mM MgCl 2 , 500 M deoxyribonucleotide triphosphate, 2.5 M random hexamers, 200 nM FAM dyelabeled probe, and forward and reverse primers at 600 nM in a final volume of 25 ml and was analyzed in an ABI PRISM 7700 (Applied Biosystems, Foster City, CA, USA) sequence detection system. Relative expression of IRAK-M mRNA levels was plotted after normalization against b-actin mRNA. The sequences used for IRAK-M and other cytokines are as follows: Cytokine-specific enzyme-linked immunosorbent assays Levels of murine TNF-a, IL-12, TGF-b and IFN-g were assessed using a modification of double-ligand method as previously described (Reddy et al., 2004) . Briefly, flatbottomed 96-well microtiter plates were coated with 50 ml/well of rabbit antibody against specific cytokines for 16 h at 4 1C. The plates were rinsed four times with wash buffer, diluted cell-free supernatants (50 ml) in duplicate were added and the samples were incubated for 1 h at 37 1C. The plates were washed again four times before adding biotinylated rabbit antibodies against the specific cytokines (50 ml/well) were and incubated for 30 min at 37 1C. After washing the plates four more times, streptavidin-peroxidase conjugate (Bio-Rad Laboratories, Richmond, CA, USA) was added, and incubated for 30 min at 37 1C. The chromogen substrate (Bio-Rad Laboratories) was added after four more washes. The plates were further incubated at room temperature to the desired extinction, and the reaction was terminated with 3 M H 2 SO 4 solution (50 1ml/well) and optical density was measured at 490 nm with an enzyme-linked immunosorbent assay reader.
Association between IRAK-M mRNA expression and survival in patients with adenocarcinoma of the lung To determine if the IRAK-M expression was predictive of patient survival, we analyzed IRAK-M mRNA levels in a cohort of 442 human lung adenocarcinomas assayed for mRNA by Affymetrix HG-U133A arrays. This is the largest available set of microarray data with extensive pathological and clinical annotation for lung adenocarcinomas (Shedden et al., 2008) . The data for IRAK-M was available for 439 out of 442 samples. For this analysis, we log-transformed mRNA expression levels using Y ¼ log 2 (max(X,0) þ 1) as in the original analysis. The data were generated at four institutions (University of Michigan Cancer Center, Moffitt Cancer Center, Memorial Sloan-Kettering Cancer Center and the Dana-Farber Cancer Institute) and we normalized values by subtracting the mean for each institution. Patients with lung adenocarcinoma were sequentially enrolled from the four institutions. Patient characteristics and the treatments they received were described previously (Shedden et al., 2008) . Consent was obtained and the project was approved by the local Institutional Review Boards. Primary tumors and adjacent non-neoplastic lung tissue were obtained at the time of surgery. Peripheral portions of resected lung carcinomas were sectioned, evaluated by a study pathologist and compared with routine hematoxylin and eosin sections of the same tumors, and used for mRNA isolation. Regions chosen for analysis contained a tumor cellularity >70%, with no mixed histology, potential metastatic origin, extensive lymphocytic infiltration or fibrosis.
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